Barclays Reiterates Buy Rating for Bruker Corporation
Barclays maintains its buy rating for Bruker, setting a price target of $60, a 1.46% downside from the current price.
Key Points
- Barclays reiterated its buy rating for Bruker Corporation (NASDAQ: BRKR) with a $60 price target on June 24, 2026.
- Barclays's $60 price target implies 1.46% downside from Bruker Corporation's ($BRKR) current $60.89 share price.
- Bruker shares traded at $55.11 on Wednesday, with a market cap of approximately $8.61 billion and a forward P/E of 23.20.
- ORBIS ALLAN GRAY LTD increased its Bruker holdings by 3,033,346 shares, while Vanguard Portfolio Management LLC opened a new position with 4,855,915 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays reiterated its buy rating for Bruker Corporation, trading under the ticker BRKR on the NasdaqGS, on June 24, 2026. Analyst Luke Sergott set a price target of $60. On the same day, Bruker's shares traded at $55.11.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Bruker Corporation
ORBIS ALLAN GRAY LTD increased its holdings in Bruker by 3,033,346 shares, bringing its total to 17,940,076 shares valued at approximately $648 million, marking a 20.3% increase. FMR LLC also grew its stake by 872,177 shares to 16,101,803 shares, valued at about $582 million, a 5.7% increase. BlackRock, Inc. added 208,821 shares, ending with 11,180,806 shares worth roughly $404 million, a 1.9% increase. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 4,855,915 shares valued at around $175 million.
Bruker Corporation Stock Up 6.7%
Shares of Bruker Corporation (NASDAQ: BRKR) traded near $55.11 on Wednesday. The company has a market capitalization of approximately $8.61 billion and a forward P/E ratio of 23.20. Bruker's stock has seen a 52-week low of $28.53 and a high of $64.54, with a 50-day moving average of $45.95 and a 200-day moving average of $41.85. The company maintains a current ratio of 1.55 and a quick ratio of 0.65, with a debt-to-equity ratio of 68.12.
$BRKR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Bruker Corporation reported revenue of about $3.46 billion, reflecting a revenue growth of 2.7%. However, the company has a negative net margin of -0.34% and a return on equity of -0.43%. The next earnings report is scheduled for August 4, 2026.
Dividend
Bruker Corporation pays an annual dividend rate of $0.20, yielding 0.35%. The dividend payout ratio stands at 38.46%.
Insider Buying and Selling at Bruker Corporation
On June 15, 2026, Mark Munch, Executive Vice President and President of Bruker Nano Inc., sold 2,000 shares at an average price of $54.76. On the same day, he also purchased 2,000 shares at $22.19. Additionally, Thierry Bernard acquired 2,886 shares on May 15, 2026.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained its buy rating for Bruker Corporation with a price target of $60. Earlier, on June 8, 2026, JP Morgan also maintained a buy rating with a target of $65. The consensus among analysts is a buy rating, with a mean price target of $53.25 based on 12 opinions.
About Bruker Corporation
Bruker Corporation, headquartered in Billerica, Massachusetts, develops and manufactures scientific instruments and analytical solutions. The company operates through segments including BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers a range of products such as magnetic resonance spectroscopy, preclinical imaging, and mass spectrometry solutions. Led by CEO Dr. Frank H. Laukien, Bruker employs approximately 11,085 people.
Bottom Line
Barclays' reiteration of its buy rating for Bruker Corporation reflects confidence in the company's prospects, despite its recent financial challenges. Investors often track these ratings to gauge market sentiment. Remember, these analyst updates are based on data as of the report date and may not reflect current conditions.
Get Bruker Corporation alerts
New 13F filings, insider trades, and analyst moves on $BRKR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.